Form 4: DexCom Director Bridgette P Heller Sells 1,000 Shares Under 10b5-1 Plan

Bridgette P Heller, a director at DexCom Inc, sold 1,000 shares of common stock on June 14, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On June 14, 2024, Bridgette P Heller, a director of DexCom Inc, sold 1,000 shares of DexCom's common stock.
• The sale was executed at a price of $113.55 per share.
• The transaction was conducted under a pre-existing 10b5-1 trading plan adopted by Ms. Heller on February 25, 2024.
• Following the transaction, Ms. Heller beneficially owns 25,349 shares of DexCom common stock, which includes 2,618 unvested restricted stock units granted on May 22, 2024.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction (insider sale under a 10b5-1 plan) and does not contain information that would significantly impact investor sentiment positively or negatively.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the restricted stock units.

Industry Context

Sales by insiders are a normal part of corporate activity. The use of a 10b5-1 plan suggests the sale was pre-planned and intended to avoid concerns about insider trading. DexCom operates in the medical device industry, specifically focusing on continuous glucose monitoring systems.

Comparison to Industry Standards

• Insider sales are common across publicly traded companies in the medical device sector, such as Medtronic, Abbott, and Boston Scientific.
• The use of 10b5-1 plans is a standard practice to ensure compliance with insider trading regulations, similar to practices observed at other companies like Insulet and Tandem Diabetes Care.
• The size of the transaction (1,000 shares) is relatively small compared to the overall trading volume of DexCom (DXCM), suggesting it is unlikely to have a significant impact on the stock price.

Stakeholder Impact

• The sale of shares by a director could have a minor psychological impact on shareholders, but the use of a 10b5-1 plan mitigates concerns about insider trading.
• The transaction is unlikely to have a direct impact on employees, customers, suppliers, or creditors.

Key Dates